Last reviewed · How we verify
NCT05865483: SwallowDM1
Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
trial in Myotonic Dystrophy 1 in 177 participants. Completed in 23 August 2024.
23 August 2024
Quick facts
| Lead sponsor | University College, London |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 177 |
| Start date | 3 July 2023 |
| Primary completion | 23 August 2024 |
| Estimated completion | 23 August 2024 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Myotonic Dystrophy 1 — all drugs for Myotonic Dystrophy 1 →
- Dysphagia, Oropharyngeal — all drugs for Dysphagia, Oropharyngeal →
Sponsor
University College, London
Who can join
18 and older, any sex, with Myotonic Dystrophy 1 or Dysphagia, Oropharyngeal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about swallowing difficulties (dysphagia) in patients living with myotonic dystrophy type 1 (DM1). The main questions it aims to answer are: * whether the size and structure of the muscles involved in swallowing differ to those without the disease * how the size and structure of muscles may associate with swallowing function and swallowing symptoms in this group. Participants will undergo a range of tests including: * Ultrasound (US) assessment of the muscles involved in swallowing * An x-ray swallowing study (known as videofluoroscopy) * Assessment of swallowing symptoms, including questionnaires * Assessments of mobility, activity and breathing * Assessments of quality of life and wellbeing
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05865483
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myotonic Dystrophy 1
Currently open trials in the same condition.
- NCT07385443 — The Spanish National Registry for Myotonic Dystrophy Type 1 · recruiting
- NCT06378216 — Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe] · recruiting
- NCT03981575 — Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) · recruiting
Other University College, London trials
Trials by the same sponsor.
- NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
- NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
- NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
- NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
- NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05865483 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University College, London
- Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05865483.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing